Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Cingulate, Inc. (CING)

Sector - Healthcare

IPO Profile

About company

They are a clinical stage biopharmaceutical company using their proprietary Precision Timed Release, or PTR, drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. They are initially focusing their efforts on the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. Their PTR platform incorporates a proprietary Erosion Barrier Layer, or EBL, designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. They are initially targeting the ADHD stimulant-based treatment market, with an estimated US market size of $15.3 billion in 2020. Stimulants are the most commonly prescribed class of medications for ADHD and account for more than 90% of all ADHD medication prescriptions in the United States, where approximately 70 million stimulant prescriptions were written last year alone. By contrast, non-stimulant medications are typically employed only in the second-line or adjunctive therapy setting and account for 9-10% of all ADHD medication prescriptions.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
13 2013

Contacts

Address: 1901 W. 47th Place Kansas City, Ks 66205

Telephone: (913) 942-2300

Web page: http://www.cingulate.com

IPO information

Expected Date 10/18/2021
Status  ! Week of
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $10.00-$12.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4.54
Shares Revised (MM) -
Expected offer amount (MM) $39.6
Realized offer amount(MM) -

Financial Data (last reporting year)

Market Cap (MM) $140.04
Revenues (MM) $0
Net Income (Loss) (MM) $-7.44

Voting

What do you think will happen with the CING share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Oppenheimer

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Oppenheimer
CO-Managers
Ladenburg Thalmann/ Brookline Capital

Sector: Healthcare

Tweets about $CING

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats